The effects of aflibercept on the viability and metabolism of ocular cells in vitro

Retina

Volumn 33, Issue 5, 2013, Pages 1056-1061

  Ammar, David A ^a   Mandava, Naresh ^a   Kahook, Malik Y ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB;

ARTICLE; CELL ASSAY; CELL CULTURE; CELL METABOLISM; CELL VIABILITY; CONTROLLED STUDY; EPITHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; SCLERA; TRABECULAR MESHWORK;

ANGIOGENESIS INHIBITORS; CELL SURVIVAL; CELLS, CULTURED; FIBROBLASTS; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL PIGMENT EPITHELIUM; SCLERA; TRABECULAR MESHWORK; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876968687     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31827b646d     Document Type: Article

References (32)

1. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695-1705.
2. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: A review. Clin Ther 2007;29:1850-1861.
3. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
4. Kahook MY, Schuman JS, Noecker RJ. Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37:144-146.
5. Kapetansky FM, Pappa KS, Krasnow MA, et al. Subconjunctival injection(s) of bevacizumab for failing filtering blebs. Invest Ophthalmol Vis Sci 2007:837.
6. Koenig Y, Bock F, Horn F, et al. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-1382.
7. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
8. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-11398.
9. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-185.
10. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-583.
11. Ohr M, Kaiser PK. Intravitreal aflibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012;13:585-591.
12. Available at: http://newsroom.regeneron.com/releasedetail. cfm?ReleaseID=629800. Accessed April 26, 2012.
13. Luthra S, Narayanan R, Marques LE, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina 2006;26:512-518.
14. Spitzer MS, Wallenfels-Thilo B, Sierra A, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol 2006;90:1316-1321.
15. Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea 2007;26: 977-982.
16. Guerriero E, Yu JY, Kahook MY, et al. Morphologic evaluation of bevacizumab (Avastin-) treated corneal stromal fibroblasts. Invest Ophthalmol Vis Sci 2006;46:1642.
17. Kernt M, Welge-Lussen U, Yu A, et al. Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells. Ophthalmologe 2007;104:965-971.
18. Qin Q, Van Bergen N, Liew D, et al. Anti-VEGF treatment on human Tenons' fibroblasts scarring activity in vitro. Invest Ophthalmol Vis Sci 2008:49:4541.
19. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837-1842.
20. Kahook MY, Ammar DA. In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells. J Glaucoma 2010;19:437-441.
21. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007; 114:2179-2182.
22. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114:855-859.
23. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053.
24. Kuo TT, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010;30: 777-789.
25. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52.
26. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007;104:18363-18370.
27. Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111-1114.
28. Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321-326.
29. Kahook MY, Liu L, Ruzycki P, et al. High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-892.
30. Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: Effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023-1034.
31. Meyer T, Robles-Carrillo L, Robson T, et al. Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice. J Thromb Haemost 2009;7: 171-181.
32. Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 2010;4:28-29.